SEC Filing Summary for Mirum Pharmaceuticals, Inc.

This filing details transactions by Christopher Peetz, Chief Executive Officer and Director of Mirum Pharmaceuticals, Inc. (MIRM). On March 15, 2026, Mr. Peetz acquired 25,000 and 50,000 shares of Common Stock through the vesting of Performance Restricted Stock Units, with these units representing a contingent right to receive one share of common stock each. These transactions resulted in post-transaction shares of 185,294 and 235,294 respectively. On March 16, 2026, 40,985 shares were disposed of to cover tax withholding obligations associated with the vesting of these units, resulting in 194,309 shares remaining. Additionally, the filing notes that 187,500 shares of Common Stock are held indirectly by The Peetz Family Trust. The filing also includes a Power of Attorney document authorizing representatives to execute SEC filings on behalf of Mr. Peetz.